Latest CD4 Stories
A cheaper laboratory test that helps guide anti-retroviral drug treatment for people with HIV/AIDS may be just as effective as a more sophisticated test, a group of international researchers has found – a discovery that could be particularly important in rural Africa.
Using highly potent antibodies isolated from HIV-positive people, researchers have recently begun to identify ways to broadly neutralize the many possible subtypes of HIV.
One of the key decisions faced by people living with HIV, and by their health-care providers, is when to start treatment.
SeraCare announced the addition of Cryo-M Human Monocytes and Cryo-T4 Human CD4+ T-Cells to its AccuCell® Peripheral Blood Mononuclear Cell (PBMC) portfolio. Milford,
In sub-Saharan Africa, only about one third of patients who test positive for HIV but are not yet eligible for antiretroviral treatment remain in care until they become eligible and start treatment.
WORCESTER, Mass. and TORONTO, July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology.
Specific types of "helper" T cells that are crucial to maintaining functioning immune systems contain an enzyme called PDI (protein disulfide isomerase).